China Journal of Chinese Materia Medica, the 1st in the field of TCM, is supervised by China Association for Science and Technology and sponsored by Institute of Chinese Pharmaceutical Association. The journal is China's earliest comprehensive core journal of traditional Chinese medicine, and always maintains the circulation top in the professional areas. The journal publishes the latest research and progress of traditional Chinese medicine and takes a leading position in numbers of articles published, downloads and citations among all journals in this discipline.
Its scope covers new achievements, technologies, methods, experiences and concepts resulting from the research on Chinese materia medica pursuant to Chinese medical and pharmaceutical theories, traditional experiences, and modern science and technology, including medicinal resources and identification, cultivation, processing, preparation, chemistry, pharmacology, theory of Chinese pharmacy and clinical practice, bencaological study.
The journal is included in CA, JST and CSCD.
Honorary Editor-in-Chief Xiao Peigen Editor-in-Chief Wang Yongyan
Associate Editors Zhang Boli, Hu Zhibi, Yao Xinsheng, Li Lianda, Li Dapeng, Yang Baofeng, Zhou Chaofan, Huang Luqi, Chen Shilin, Li He.
Executive Editorial Board Cai Shaoqing, Chen Shilin
To study the effect of polysaccharides from
Polygonatum sibiricum on mRNA and protein expressions of blood lipid metabolism in hyperlipidemic mice. The mice were randomly divided into six groups, namely the blank control group, the hyperlipidemia model group, the simvastatin group, and low, middle and high-dose PSP groups (200, 400, 800 mg·kg
–1·d
-1). Each group of the mice was administrated intragastrically for 14 days, respectively. Subsequently, every group of mice, except for the blank control group, was intraperitoneally injected with 75% fresh egg yolk emulsion for establishing the hyperlipidemic mice model. Upon completion of the administration, the contents of TC, TG, LDL-C and HDL-C in serum of each group were investigated in details. In particular, the mRNA expression levels of PPAR-
α, PPAR-
β, PPAR-
γ, SREBP-1c, IL-6 and TNF-
α of the liver tissues were detected by Real-time PCR, and the protein expression levels (including PPAR-
α, PPAR-
β, PPAR-
γ, SREBP-1c, IL-6, TNF-
α) were examined by Western blot. Consequently, the obtained results showed that the contents of the serum TC, TG, LDL-C of low, middle and high-dose PSP groups significantly decreased compared with those of the hyperlipidemia model group. Simultaneously, there were significant differences between middle-dose and high-dose PSP groups (
P < 0.01). In striking contrast, the contents of serum HDL-C of low, middle and high-dose PSP groups significantly increased, while obvious differences were also observed between middle-dose and high dose PSP groups (
P < 0.01). Moreover, middle-dose and high-dose PSP groups could up-regulate the protein and mRNA expressions of PPAR-
α, PPAR-
β (
P < 0.05) compared with those of the hyperlipidemia model group, and down-regulate the expressions of PPAR-
γ, SREBP-1c, IL-6 and TNF-
α (
P < 0.05) compared with those of liver tissues of the hyperlipidemia model group. In conclusion, all of the above results suggested that PSP could inhibit the oxidation of the liver lipid, and regulate the expression levels of the corresponding genes and proteins relating to the lipid metabolism, so as to play a critical role for preventing hyperlipidemia.
A new naphthalene derivative and three known compounds were isolated from the petroleum ether extract of the bulbs of
Eleutherine americana by using various chromatographic techniques, such as column chromatography over silica gel and semi-preparative HPLC. Their structures were elucidated by spectroscopic date (MS, UV, IR, NMR), which were identified as eleutherol B (
1), 4,8-dihydroxy-3-methoxy-1-methylanthraquinone-2-carboxylic acid methyl ester (
2), 8-hydroxy-3,4-dimethoxy-1-methylanthraquinone-2-carboxylic acid methyl ester (
3), and isoeleutherine (
4). Compound
1 is a new compound. The diastolic blood vessels activity of compounds
1 and
2 were potent, reaching 82.5% and 85.3% at the concentration of 10 μmol·L
-1, which were basically the same as that of the positive drug tanshinone Ⅱ
A.
Hyaluronic acid (HA) and cell-penetrating peptide (CPP) R
6H
4-SA modified artesunate nanostructured lipid carrier (HA-R
6H
4-NLC/ART) for anti-tumor therapy was prepared. The physicochemical properties and in vitro drug release of HA-R
6H
4-NLC/ART were evaluated, and the uptake and cytotoxicity of liver cancer HepG 2 cells were studied. The results showed that HA-R
6H
4-NLC/ART was spherical like in appearance, and the average particle size was about 160 nm. In vitro release experiments showed that the drug delivery system had sustained release characteristics. Cell results showed that, in slightly acidic environment, pH sensitive CPP R
6H
4-SA mediated cellular uptake of nanoparticles was significantly higher than that of non-sensitive peptide R
8-SA. Meanwhile, HA-R
6H
4-NLC/ART had a targeting effect on HepG 2 cells, and the HA receptor saturation experiment showed that the endocytosis of HA-
R6H4-NLC/ART was mediated by the HA receptor on the cell surface. As compared with the unmodified or R
6H
4-SA single modified group, HA and R
6H
4-SA co-modified HA-R
6H
4-NLC/ART significantly improved the cell uptake and had a stronger anti-tumor effect under the conditions of the slightly acid environment and hyaluronidase degradation. The above results showed that hyaluronic acid and CPP R
6H
4-SA co-modified artesunate nanostructured lipid carrier, which can effectively identify and penetrate the tumor cell membrane into the cell, is a potentially efficient targeting delivery system for anti-tumor drugs.
An ultra-performance liquid chromatography-tandem mass spectrometric method (UPLC-MS/MS) was developed in this study to simultaneously determine the contents of eight effective constituents in rat plasma, including baicalin, wogonoside, baicalein, liquiritin, glycyrrhizic acid, berberine hydrochloride, saikosaponin a and saikosaponin d in plasma of gastric ulcer rats, and investigate the pharmacokinetics of Modified Xiaochaihu Granules. Chromatographic separation was conducted on Zorbax SB-C
18 column (2.1 mm × 100 mm, 1.8 μm) with acetonitrile-0.1% formic acid aqueous solution as the mobile phase for gradient elution, at a flow rate of 0.4 mL·min
–1 and column temperature of 40 °C. Detection was performed in the multiple reaction monitoring (MRM) mode with ESI ion source. All calibration curves showed good linearity (
r > 0.996) over a wide concentration range for all constituents. RSDs of intra-day and inter-day precision were all within 15% and the extraction recoveries of all the constituents were in the range of 81.92% to 104.8%. The time to peak (
tmax) of these eight constituents was (2.69 ± 2.02), (5.17 ± 2.04), (0.25 ± 0), (0.83 ± 0.26),(0.92 ± 0.20), (0.92 ± 0.20), (0.58 ± 0.20), and (0.083 ± 0) h, respectively; the half-life (
t1/2) of them was (7.85 ± 0.34), (10.16 ± 2.21), (6.79 ± 0.21), (8.32 ± 0.48), (11.05 ± 1.78), (11.56 ± 3.46), (15.30 ± 1.84), and (5.54 ± 1.91) h, respectively; the peak concentration (
Cmax) of them was (55.02 ± 1.67), (213.66 ± 4.62), (62.61 ± 0.69), (68.43 ± 1.42), (62.22 ± 0.39), (30.17 ± 1.89), (61.79 ± 4.81), and (38.02 ± 1.75) μg·L
–1, respectively. This established method is simple and accurate with good repeatability and strong specificity, which could provide modern experimental basis for modified Xiaochaihu granules in clinical treatment of gastric ulcer.
